Carmat elects heart industry veterans to board
This article was originally published in Clinica
Carmat, a Velizy, France-based start-up developing a fully-implantable artificial heart for late-stage heart failure patients, has expanded its board of directors with three new members. They are: André-Michel Ballester, CEO of Italian cardiovascular device company Sorin; Peter Steinmann, former vice-president of Medtronic, and Michel Finance, acting CEO of Carmat. This brings the total number of board directors to six. The other members include chairman Jean-Claude Cadudal, founder and chief scientific officer Professor Alain Carpentier, and general partner of Truffle Capital, Dr Philippe Pouletty.